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Abstract
Recently, there has been a surge of early phase trials of molecularly targeted agents (MTAs) and 
immunotherapies. These new therapies have different toxicity profiles compared to cytotoxic 
therapies. MTAs can benefit from new trial designs that allow inclusion of low-grade toxicities, 
late-onset toxicities, addition of an efficacy endpoint, and flexibility in the specification of a target 
toxicity probability. To study the degree of adoption of these methods, we conducted a Web of 
Science search of articles published between 2008 and 2014 that describe phase 1 oncology trials. 
Trials were categorized based on the dose-finding design used and the type of drug studied. Out of 
1,712 dose-finding trials that met our criteria, 1,591 (92.9%) utilized a rule-based design, and 92 
(5.4%; range 2.3% in 2009 to 9.7% in 2014) utilized a model-based or novel design. Over half of 
the trials tested an MTA or immunotherapy. Among the MTA and immunotherapy trials, 5.8% 
used model-based methods, compared to 3.9% and 8.3% of the chemotherapy or radiotherapy 
trials, respectively. While the percentage of trials using novel dose-finding designs has tripled 
since 2007, only 7.1% of trials use novel designs.
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phase 1 designs; dose-finding methods; targeted therapy; immunotherapy; optimal dose; maximum 
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1. Introduction
Dose-finding trials test new drugs or combinations of drugs with the goal of identifying a 
tolerable dose to be used in subsequent trials. In oncology, study designs for these trials were 
initially developed for testing cytotoxic agents, with the goal of determining the maximum 
tolerated dose (MTD). The primary outcome of these trials is usually binary, defined as the 
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presence or absence of a dose limiting toxicity (DLT) in the first cycle of treatment based on 
the Common Terminology Criteria for Adverse Events (CTCAE) (NIH, 2009; NCI, 2014). 
The underlying assumption in phase 1 cancer trials is that the probability of toxicity 
monotonically increases with dose, and that doses with higher probabilities of toxicity yield 
higher probabilities of response (Green et al., 2012). Dose-finding methods for phase 
1cancer trials can be broadly categorized into rule-based/algorithmic designs, such as the 
‘3+3’ design (Storer, 1989), and model-based designs. The latter category includes the 
Continual Reassessment Method (CRM) (O’Quigley et al., 1990), its variations such as 
Time-to-Event CRM (TITE-CRM) (Cheung and Chappell, 2000) and modified CRM 
(Goodman et al., 1995; Piantadosi et al., 1998; Yuan et al., 2007), and Escalation with 
Overdose Control (EWOC) design (Babb et al., 1998). Compared to rule-based designs, 
model-based methods require a smaller sample size to achieve the same precision in 
estimation of the MTD and assign a higher proportion of patients to levels closer to the true 
MTD. Moreover, they allow more flexibility in the specification of a target probability of 
DLT. Despite these advantages, the adoption of model-based designs has been slow. Rogatko 
et al. (2007) reported that 98.4% of phase 1 dose-finding cancer trials published from 1991 
to 2006 utilized a rule-based design. Le Tourneau et al. (2009) performed a similar review of 
articles published between 2007 and 2008 and concluded that 96.7% of dose-finding trials 
used rule-based algorithms.
In recent years, the landscape in cancer drug development has changed with more 
molecularly targeted agents (MTAs) and immunotherapies being tested in clinical trials. 
Starting in 2008, the number of Food and Drug Administration (FDA) approved MTAs has 
increased rapidly, with more than 60 MTAs available today for cancer treatment (NCI, 
2014). These new MTAs and immunotherapies have distinct molecular pathways, which lead 
to different toxicity profiles compared to cytotoxic agents. A recent study reported that 25% 
of early phase MTA clinical trials defined grade 2 toxicities as a DLT (Le Tourneau et al., 
2011). Moreover, the extended periods over which these therapies are administered raise 
concerns regarding late-onset and cumulative toxicities (e.g., rashes, fatigue, diarrhea and 
neuropathy), which affect patients’ quality of life (Verweij et al., 2010; Wigertz et al., 2012, 
Blay and Rutkowski, 2014). Furthermore, the dose-efficacy and dose-toxicity relationships 
may differ from those of cytotoxic agents, raising the possibility that efficacious doses may 
be found below the MTD (Korn, 2001; Parulekar and Eisenhauer, 2004; Cannistra, 2008; 
Moreno Garcia et al., 2014).
Given the aforementioned differences between cytotoxic agents and MTA / 
immunotherapies, the definitions of DLT and MTD, as well as the methods used to estimate 
the optimal dose need to be re-evaluated (Soria, 2011). Recent methods have been proposed 
to:
1. Account for late-onset toxicity without interrupting recruitment (Cheung and 
Chappell, 2000; Ivanova et al., 2016)
2. Allow for the specification of multiple toxicity thresholds, for example, 
thresholds for low and moderate grade toxicity (Lee et al., 2011; Cheng and Lee, 
2015)
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3. Estimate the MTD for combination therapies (Mandrekar et al., 2007; 
Mandrekar, 2014; Wages and Conaway, 2014)
4. Take into account toxicity and efficacy simultaneously (Braun, 2002; Ivanova, 
2003; Thall and Cook, 2004; Zhang et al., 2006; Dragalin and Fedorov, 2006).
The acute need of implementing new methods for testing novel anticancer agents, led us to 
evaluate the use of statistical designs from 2008 to 2014. Not only the literature of dose-
finding reviews needed an update (last ones covered 1991 – 2008: Rogatko et al., 2007; Le 
Tourneau et al., 2009), but the number of novel agents has increased substantially in these 
seven years. Our review complements the recent article on drug-combinations published by 
Riviere et al. (2015) and the article by Iasonos and O’Quigley (2014), with additional 
findings on single agents use, classification by therapy type (chemotherapy, radiotherapy, 
MTA and immunotherapy), and an updated list of trials implementing model-based designs. 
In addition, we redesign two trials that used the ‘3+3’ design to see how they would have 
benefitted from using a model-based approach instead.
2. Methods and Classification
A Web of Science (WOS) search was conducted on November 2, 2015 to identify phase 1 
oncology trial articles published between 2008 and 2014. Only trials aimed at estimating the 
MTD were included, regardless of the number of investigational agents being tested. The 
database and the search criteria were selected based on the previous literature review 
performed by Rogatko et al. (2007) to provide continuity and comparability to the last major 
review evaluating dose-finding methods. The exact search criteria can be found in Appendix 
1. Studies were grouped into four categories:
1. Animal studies (studies solely in animals)
2. Statistical/methodological studies (papers that proposed new designs or 
reviewed, compared and addressed other methodological considerations without 
having an explicit dose-finding trial published during our time frame of interest)
3. Dose-finding studies (articles in which the goal was to find the MTD)
4. Other (articles that did not fall under the aforementioned categories, such as 
articles discussing phase 2 studies, providing an overview of a drug’s PK/PD, or 
reviewing the entire drug development process for a particular agent).
Further classification of the dose-finding studies was based on the type of statistical design 
employed, as follows:
1. Dose-Escalation (model-based or novel designs)
Dose-Escalation (CRM), studies using the Continual Reassessment Method 
or its variations,
Dose-Escalation (EWOC), studies using the EWOC design or its variations,
Dose-Escalation (Novel designs), studies using a statistical methodology 
specifically tailored for the published study or other novel designs such as 
the ‘Cumulative Cohort Design’ by Ivanova and Chung (2007).
Chiuzan et al. Page 3
J Biopharm Stat. Author manuscript; available in PMC 2018 February 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
2. Dose-Escalation (‘A+B’), studies using rule-based algorithms, such as the ‘3+3’ 
design, the rolling six design (Skolnik et al., 2008) or the accelerated titration 
design (Simon et al., 1997).
3. Dose-Escalation (Other), studies using none of the above methods. These were 
primarily dose-finding studies that used intra-patient dose-escalation or studies 
that did not provide enough detail regarding the method used to assign patients to 
doses and estimate the MTD.
Two readers reviewed each article independently and assigned a study category. If 
discrepancies were found, a third reader was asked to review the inconsistent articles. 
Furthermore, the literature search was supplemented by a review of all articles published on 
Google Scholar between 2008 and 2014 that cited the original CRM, the modified CRM, the 
TITE-CRM, or the EWOC. Given that these were the most often used designs, the 
supplementation was performed to provide an updated list of trials using model-based 
designs, and to provide a conservative estimate of the uptake of these methods. Dose-finding 
studies from the reference search were matched against the original list of model-based and 
novel designs from the WOS search. Studies that were unique to the reference search were 
reviewed, and included only if the design used was among one of the four categories 
mentioned above. For model-based and novel designs, the pre-specified dose information 
used in the design phase of the trial, the sample size, the number of evaluable patients, the 
type of entity that sponsored the study, and the specific statistical design were recorded.
The types of investigational agents were recorded and categorized for all dose-finding 
studies. The classification was based on the escalating agent, as chemotherapy, radiotherapy, 
MTA, immunotherapy, or other. The chemotherapy category represented classical 
antimetabolites and included novel chemotherapeutic agents such as TAS-106 and 
Vosaroxin. The radiotherapy category included radiation therapy, radiation chemotherapy, 
radioimmunotherapy, radioembolization, and radiosensitizers. MTAs were defined as agents 
that specifically inhibited or manipulated a specific actionable target (other than 
antimetabolites that were categorized as chemotherapy). Trials that escalated both the 
chemotherapy agent and the MTA were classified as MTA. The immunotherapy category 
included check-point blockers, cytokines (other than pegfilgastrim), vaccines, viral agents, 
NGR-hTNF, and bromohydrin pyrophosphate (IPH 1101). When both chemotherapy and 
immunotherapy were escalated, the trial was classified as immunotherapy. ‘Other’ category 
included agents that were unable to be represented by the aforementioned categories, such as 
Tariquidar, lenalidomide, hypericin, denibulin, hylaronic acid, PHY-906, steroids, and 
boorotene. One study used as an illustrative example and published in a statistical journal 
was also classified in the ‘Other’ category.
All results are presented in tables as frequency counts and percentages. The number of 
studies using model-based or novel designs was calculated given the type of agent and year 
of publication. The time trend for each agent type was also tabulated separately. A separate 
section was included in the paper to illustrate two case examples of trials that would have 
benefitted from the use of a model-based design, but used the ‘3+3’ design instead.
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3. Results
Of the 1,933 records identified on Web of Science, 20 were excluded because of duplicates, 
non-existing article links, published in a language other than English or published in print 
after 2014. Of the remaining 1,913 studies, 1,693 discussed phase 1 dose-escalation 
oncology trials, 29 were animal studies, 76 were statistical or methodological articles, and 
115 were in the other category. The supplementary Google Scholar search produced 19 
additional articles that utilized the CRM, variations of the CRM, or the EWOC.
Among the 1,712 articles that described dose-escalation trials, rule-based ‘A+B’ designs 
were used in 1,591 (92.9%) studies. Model-based or novel designs were used in 92 (5.4%) 
studies, of which 59 (64.1%) used the CRM or its variations, 24 (26.1%) used the EWOC or 
its variations, and the rest used other trial specific designs (see Figure 1). The percentage of 
studies utilizing model-based or novel designs varied throughout the years, ranging from 
2.3% in 2009 to 9.7% in 2014 (Table 1). The percentage of studies using the CRM or 
EWOC ranged from 0.9% in 2009 to 6.1% in 2011, and from 0% in 2008 to 4.9% in 2014, 
respectively.
Classification by type of therapy tested in phase 1 trials identified 853 (49.8%) trials of 
MTAs, 85 (5.0%) of immunotherapies, 609 (35.6%) of chemotherapies, 60 (3.5%) of 
radiotherapies, and 105 (6.1%) of other agents. As shown in Table 2, the percentage of trials 
investigating MTAs has increased sharply. In 2013 and 2014, 63% of all published dose-
escalation trials tested a targeted agent. Across all years, 50 out of the 853 (5.9%) trials 
testing MTAs used a model-based or novel design, ranging from 3.1% in 2009 to 9.8% in 
2014. For chemotherapy, 24 (3.9%) used a model-based or novel design, ranging from 0% in 
2009 to 13.8% in 2014. For immunotherapy, radiotherapy and ‘other’ category, the number 
of trials that used a model-based or novel design was 5 out of 85 (5.9%), 5 out of 60 (8.3%) 
and 8 out of 105 (7.6%), respectively.
A more detailed classification of the 92 dose-escalation studies that employed a model-based 
or novel design is shown in the Appendix 2. Of these 92 studies, more than 25% were 
designed using a continuous dose range or did not explicitly state the discrete set of dose 
levels used in the design. For studies employing discrete dose levels, the range varied from 2 
to 16 with total sample sizes ranging from 9 to over 100. Academic institutions (48%) and 
industry-sponsored trials (41%) were the major contributors of these studies. The majority of 
the 92 trials (62%) were multicenter.
4. Redesigned Examples
Case Study 1
We redesigned two studies that used the ‘3+3’ design, but could have benefitted from the use 
of a model-based design. The study in Ghamande et al. (2014) was a phase 1 trial to 
determine the MTD of a novel camptothecin in patients with advanced solid tumors. A total 
of 54 patients were enrolled at 11 dose levels using the ‘3+3’ design. However, one of the 
doses was not specified a priori, but added during the trial as an intermediate level, after 
seeing 2 DLTs out of 6 patients at dose number 8. This ad-hoc approach not only 
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contravened with the trial conduct, but it also affected the choice of the final MTD. If the 
original set of doses had been used, the trial would have stopped earlier (after enrolling 32 
patients), and a lower dose level (dose level 8) would have been declared as the MTD. The 
protocol amendment increased the total sample size to 54 patients and declared dose level 10 
as the MTD. With such a large number of dose levels, using the ‘3+3’ design can be 
inefficient and lead to a large sample size, like in this example. The study would have 
benefitted from using the CRM with assigning patients in cohorts of size 1 for faster 
escalation. Alternatively, rather than selecting a dose from a pre-specified set of 11 dose 
levels, since the drug was administered intravenously, a dose could be selected from a 
continuum of doses. We performed simulations to compare the ‘3+3’ design to the CRM 
with dose level 1 as the starting dose and a target DLT probability of 0.25 (see Table 3). We 
chose the target DLT probability of 0.25 since it has been shown that on average the ‘3+3’ 
design targets DLT probabilities between 0.16 and 0.27. (Ivanova, 2006). The CRM with an 
empirical dose-toxicity model and a vague normal prior distribution for the model 
parameter, β ~ N(0,1.34), was used (O’Quigley and Shen, 1996). A total of 2,000 
simulations were run for the CRM and the ‘3+3’ using the statistical software R (2014). 
Using the CRM with cohorts of size 1 and a total sample size of 54 patients, the probability 
of selecting dose level 10 as the MTD was 63%, with an average of 23 patients treated at the 
MTD. In comparison, the ‘3+3’ design selected dose level 10 (with the true probability of 
DLT of 0.25) as the MTD 29% of the time, and selected dose level 9 (with the true 
probability of DLT of 0.15) 33% of the time. This indicates that the ‘3+3’ design is more 
likely to select a dose with DLT probability of 0.20 or lower rather than higher probabilities 
such as 0.25 or 0.30. Since the mean sample size for the ‘3+3’ design was 34 patients, and 
the total sample size of the trial before the protocol amendment was 32 patients, we also 
simulated the CRM with a sample size of 32 patients. The CRM selected the correct MTD 
54% of the time with an average of 11 patients being assigned to this dose level. Thus, the 
CRM is more efficient in estimating the dose with the DLT probability of 0.25 compared to 
the ‘3+3’ design. It also assigns more patients to the true MTD on average.
Case Study 2
Chen et al. (2014) reported the results of a phase 1 trial of maintenance sorafenib after stem 
cell transplantation in patients with acute myeloid lymphoma. The ‘3+3’ design with an 
expansion cohort was used to identify the MTD out of three dose levels. A DLT was defined 
as a grade 3 or higher treatment-related toxicity in the first 28 days that did not resolve 
within 14 days after suspending sorafenib. Twelve patients were used to identify the MTD, 
which was the highest dose level, and 10 additional patients were treated at that dose level. 
While only 1 DLT out of 6 was observed at the highest dose during the initial DLT window 
(28 day cycle), later on, 5 (31%) additional patients had to discontinue treatment due to 
toxicities possibly related to treatment. In this case late-onset toxicities may be contributing 
to a poorly tolerated dose. Thus, defining the MTD based on a longer time interval and using 
a design like the TITE-CRM, which accounts for late-onset toxicities, can help identify a 
better-tolerated dose. The TITE-CRM utilizes data in real time including data from patients 
still in follow-up, allows for enrollment of patients before previously enrolled patients 
complete the DLT evaluation window, and thus can significantly reduce the length of the 
trial. Table 4 compares the operating characteristics based on 2,000 simulations of the TITE-
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CRM versus the ‘3+3’ algorithm using the DLT probabilities observed during a longer time 
interval. For the TITE-CRM, we extended the DLT evaluation window to two cycles, and 
used sample sizes with (N = 22) and without the expansion cohort (N = 12). The target DLT 
probability was set at 0.20 with dose level 1 as the starting dose level and cohorts of size 1. 
The TITE-CRM used an empirical dose-toxicity model with a vague normal prior 
distribution as in the first case study.
Extending the DLT evaluation window to capture delayed toxicities might lead to a different 
MTD. When accounting for delayed toxicities, the TITE-CRM identified dose level 2 as the 
MTD 80% and 70% of the time, for N = 22 and N = 12, respectively, compared to 48% for 
the ‘3+3’ design with an average sample size of 11 patients. In addition, under the TITE-
CRM, the average number of patients treated at the MTD was 13 and 6 for sample sizes of 
22 and 12, respectively.
5. Discussion
This study reviews dose-finding oncology trials published between 2008 and 2014 with the 
goal of providing updated statistics on trial design methodology. The review was motivated 
by the increased number of MTAs and immunotherapies, which bring new challenges in 
identifying the dose for subsequent phase 2 trials. The percentage of dose-finding studies 
that used a model-based or novel design between 2008 and 2014 has more than tripled since 
the last major review of the literature in 2007. However the actual fraction remains low 
(1.6% for the period of 1991–2006 versus 5.4% for the period of 2008 to 2014). While the 
percentage of trials using novel designs fluctuates from year to year, there seems to be a 
slight increase in the implementation of model-based or novel designs over time. Our 
findings indicate that from 2011 to 2014, the percentage of trials that employed model based 
or novel designs for testing MTAs approached 7%, double compared to previous years. 
However, this remains far below the desirable rate at which these new methods should be 
adopted. The recent post-marketing dose-optimization studies performed on several MTAs 
have made investigators reconsider the use of conventional dose-finding designs in the 
context of the new anticancer treatments (Minasian et al., 2014). In recent meetings 
convened by the FDA and the American Association of Cancer Research (AACR) in May of 
2015 and 2016, a call was made in favor of using model-based methods, as they are more 
flexible in considering different toxicity profiles.
In order to provide a more complete and updated list of trials using CRM and EWOC, we 
supplemented our original search with model-based designs using citations from Google 
Scholar. Thus, the estimate of 5.4% may even be an overestimate of the true proportion of 
trials using model-based or novel designs. It should also be noted that this review was 
limited to published studies and our search criteria included “maximum tolerated dose”. As 
a result, we are only capturing information on published dose-finding studies aimed at 
estimating the MTD, and studies identifying biologically optimal dose or minimum effective 
dose may not be included. A search on www.clinicaltrials.gov was attempted to identify 
unpublished studies, but very limited information was available on the dose-finding 
methodology.
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Reluctance to adopt new designs can be due to many factors. It is possible that not all 
clinical investigators or biostatisticians are familiar with or even aware of these methods 
(Jaki, 2013). Also, model-based and novel dose-escalation designs require close 
collaboration with statisticians and access to software and computational resources (Gonen, 
2009; Jaki, 2013). These obstacles can be addressed through greater educational initiatives 
around model-based designs for statisticians in academia, pharmaceutical industry, or 
consortiums, and additional software development to facilitate the execution of model-based 
designs. In 2015, the AACR offered a biostatistics workshop focused on clinical trial designs 
for targeted agents for junior statisticians working in oncology. Short courses on phase 1 
designs have been offered frequently at major statistical conferences such as the Society for 
Clinical Trials (SCT) Meeting, the International Biometric Society Eastern North American 
Region (ENAR) Meeting, and the American Statistical Association Joint Statistical Meeting 
(JSM). Another major obstacle is the misconception that model-based designs lead to 
observing more toxicities on average compared to the ‘3+3’ design. To the contrary, the 
average proportion of toxicities in these studies is acceptable and does not exceed the 
conventional DLT ceiling of 0.25–0.33. In a recent article, Iasonos and O'Quigley (2014) 
showed that in trials implementing model-based design such as CRM, TITE-CRM or 
EWOC, the average DLT probability was 0.18. An ultimate barrier is motivation and time 
(Gonen, 2009). At many institutions, statisticians have limited time to explore and 
implement novel methods. Even for statisticians who are aware and familiar with these 
designs, applying them requires more effort than the conventional ‘3+3’ designs.
With the different toxicity profiles displayed by MTAs and immunotherapy, it is becoming 
necessary and important to consider novel designs for dose-finding trials of new anticancer 
agents. Model-based designs can offer increased flexibility and efficiency compared to rule-
based designs, as illustrated in the case examples presented above. In these examples, the 
novel methods would have improved the trial by decreasing the sample size and even 
identifying a different recommended dose level to be carried forward given the inclusion of 
late-onset or cumulative toxicities. While the '3+3' design is simple to implement, model-
based designs are superior in quality of estimation of the MTD, in reducing trial duration, 
and in flexibility of defining the optimal dose.
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Appendix 1
Search term:
TOPIC: ("phase I" OR "phase 1" OR "phase one") AND TOPIC: (study OR studies OR 
trial)
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AND TOPIC: (maximum tolerated dose)
Refined by: DOCUMENT TYPES=(ARTICLE) AND RESEARCH 
AREAS=(ONCOLOGY)
Timespan=2008–2014
Search language=Auto
Appendix 2
Table of the characteristics of dose-finding trials that used model-based or novel designs
Year First Author Design N* Dose Levels MTD drug type† Entity Center Type
2008 Adkison Novel 47 Various Radiotherapy Academic One Center
2008 De Bono CRM 39 7 Targeted therapy Industry Two Centers
2008 Grossman CRM 12
18
Continuous Chemotherapy Consortium Multicenter
2008 Guillot CRM 31 4 Chemotherapy Academic Multicenter
2008 Gururangan CRM 16
19
Continuous Chemotherapy Consortium Multicenter
2008 Jimeno CRM 21 Continuous Targeted therapy Academic One Center
2008 MacDonald CRM 31 Continuous Targeted therapy Consortium Multicenter
2008 Neuenschwander CRM 24 15 Other therapy Industry Multicenter
2008 Rao CRM 17 5 Chemotherapy Academic One Center
2008 Saji CRM 17 5 Chemotherapy Academic Multicenter
2008 Truemper CRM 41
78
4
4
Chemotherapy Academic Multicenter
2009 Bailey Novel 50 5 Targeted therapy Industry Multicenter
2009 Borghaei EWOC 39
13
Continuous Immunotherapy Academic Multicenter
2009 Demetri EWOC 53 3 Targeted therapy Industry Multicenter
2009 Li CRM 27 Continuous Immunotherapy Academic One Center
2009 Loeb CRM 13 Continuous Radiotherapy Academic Two Centers
2010 Andre TITE-
CRM
23
10
3
4
Targeted therapy Industry Multicenter
2010 Fouladi CRM 29
21
Continuous Targeted therapy Consortium Multicenter
2010 Furman TITE-
CRM
18 3 Targeted therapy Academic Multicenter
2010 O'Donnell CRM 14
15
4 Chemotherapy Academic One Center
2010 Peereboom CRM 16
21
Continuous Chemotherapy Consortium Multicenter
2010 Rathkopf EWOC 8
8
Continuous Targeted therapy Industry Multicenter
2011 Fouladi CRM 9 2 Targeted therapy Consortium Multicenter
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Year First Author Design N* Dose Levels MTD drug type† Entity Center Type
2011 Gandhi CRM 35
12
Continuous Targeted therapy Industry Multicenter
2011 Geoerger CRM 29
21
4 Targeted therapy Consortium Multicenter
2011 Jakubowiak TITE-
CRM
30
20
3
4
Other therapy Industry Multicenter
2011 Jerusalem TITE-
CRM
40 4 Targeted therapy Industry Multicenter
2011 Kim CRM 27 4 Targeted therapy Industry Multicenter
2011 Koolen CRM 32
10
5
2
Chemotherapy Industry Multicenter
2011 Magenau TITE-
CRM
46 3 Chemotherapy Academic One Center
2011 Mehnert CRM 16 Continuous Targeted therapy Academic One Center
2011 Satoh CRM 20
21
3
4
Chemotherapy Academic Multicenter
2011 Smith CRM 32 Continuous Targeted therapy Academic One Center
2011 Terakura CRM 17 Continuous Chemotherapy Academic Multicenter
2011 Vansteenkist TITE-
CRM
24
19
3
3
Targeted therapy Industry Multicenter
2011 Warren CRM 38 Continuous Other therapy Consortium Multicenter
2011 Di Stasi CRM 5 3 Immunotherapy Academic One Center
2012 Ben-Josef TITE-
CRM
50 6 Radiotherapy Academic Two Centers
2012 Bendell EWOC 30 Continuous Targeted therapy Industry Multi center
2012 Crew TITE-
CRM
30 3 Other therapy Academic Multicenter
2012 Farid CRM 18 6 Chemotherapy Government One Center
2012 Feng TITE-
CRM
23 11 Other therapy Academic One Center
2012 Geletneky CRM 18 3 Immunotherapy Academic One Center
2012 Jakubowiak TITE-
CRM
35 3 Targeted therapy Academic Multicenter
2012 Jones Novel 21 12 Targeted therapy Academic One Center
2012 Kawahara CRM 18 3 Chemotherapy Consortium Multicenter
2012 Lu CRM 31 Continuous Targeted therapy Academic One Center
2012 Markman EWOC 57 Continuous Targeted therapy Industry Multicenter
2012 Mazard CRM 17
11
5
7
Chemotherapy Academic One Center
2012 Moulder CRM 15 4 Targeted therapy Academic One Center
2012 Reardon EWOC 16 Continuous Targeted therapy Industry Multicenter
2012 Roberts CRM 15
14
Continuous Targeted therapy Industry Multicenter
2012 Schneider TITE-
CRM
12 7 Targeted therapy Academic Multicenter
2012 Sinha EWOC 19 6 Targeted therapy Academic One Center
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Year First Author Design N* Dose Levels MTD drug type† Entity Center Type
2012 Tevaarwerk TITE-
CRM
24 Continuous Other therapy Academic One Center
2012 Tsien TITE-
CRM
38 5 Radiotherapy Academic One Center
2012 Foster Novel 20 5 Targeted therapy Academic Multicenter
2013 Angevin EWOC 19 Continuous Targeted therapy Industry Multicenter
2013 Cannon Novel 79 Various Radiotherapy Academic One Center
2013 Chiappella CRM 21 4 Other therapy Academic Multicenter
2013 DeAngelo EWOC 39
23
28
20
Continuous Targeted therapy Industry Multicenter
2013 Finn EWOC 25 Continuous Targeted therapy Industry Multicenter
2013 Harvey EWOC 30 Continuous Targeted therapy Academic One Center
2013 Larocca CRM 24 4 Other therapy Academic Multicenter
2013 Mangiacavalli CRM 24 2 Chemotherapy Academic One center
2013 Schott TITE-
CRM
30 4 Targeted therapy Academic Multicenter
2013 Sessa EWOC 101 Continuous Targeted therapy Industry Multicenter
2013 Sharma EWOC 22
6
19
8
5
5
3
2
Targeted therapy Industry Multicenter
2013 Thornton CRM 15 5 Targeted therapy Industry One Center
2013 Cruz CRM 8 3 Immunotherapy Academic One Center
2014 Besse TITE-
CRM
22
18
4
4
Targeted therapy Industry Multicenter
2014 Das CRM 18 4 Chemotherapy Academic One Center
2014 Fanale EWOC 111 Continuous Targeted therapy Industry Multicenter
2014 Gandhi Novel 60 16 Targeted therapy Industry Multicenter
2014 Brennan EWOC 16 7 Chemotherapy Industry One Center
2014 Isakoff Novel 32 9 Targeted therapy Industry Multicenter
2014 Brana Novel 47 4
2
Targeted therapy Industry Multicenter
2014 Iyer EWOC 26 4 Targeted therapy Industry Multicenter
2014 Tsimberidou Novel 27 3 Chemotherapy Industry One Center
2014 Infante EWOC 53 Continuous Targeted therapy Industry Multicenter
2014 Doi EWOC 31 7 Targeted therapy Industry Multicenter
2014 Rodon EWOC 83 7 Targeted therapy Industry Multicenter
2014 Boulin CRM 21 5 Chemotherapy Academic One Center
2014 Faderl CRM 30
20
4 Chemotherapy Academic One Center
2014 Rodon EWOC 73
30
7
3
Targeted therapy Academic Multicenter
2014 Saura EWOC 17 2 Targeted therapy Industry Multicenter
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Year First Author Design N* Dose Levels MTD drug type† Entity Center Type
2014 Shaw EWOC 130 6 Targeted therapy Industry Multicenter
2014 Ando EWOC 15 3 Targeted therapy Industry One Center
2014 Khouri CRM 56 4 Chemotherapy Academic One Center
2014 Kobayashi CRM 18
15
6
4
Chemotherapy Industry Multicenter
2014 Popovtzer CRM 25 5 Chemotherapy Academic One Center
2014 Sharma EWOC 40
33
7
6
Targeted Industry Multicenter
Abbreviation: CRM, Continual Reassessment Method; EWOC; Escalation with Overdose Control
*
Evaluable N, Multiple rows indicate trials with multiple arms
†
MTD drug type ‘Other’ category includes one unspecified agent
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Figure 1. Classification of the reviewed dose-finding oncology studies published between 2008–
2014
CRM: Continual Reassessment Method; EWOC: Escalation with Overdose Control
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Table 4
Case Study 2: Probability of selecting each dose as the maximum tolerated dose (MTD). Results for the true 
MTD are in bold.
Dose
1
Dose
2
Dose*
3
Assumed DLT probabilities
used in simulations
0 0.20 0.40
‘3+3’ design (N = 11)** 0.29 0.48 0.23
TITE-CRM (N = 22) 0.07 0.80 0.13
TITE-CRM (N = 12) 0.14 0.70 0.16
*
MTD declared by the end of the original trial was later deemed unsafe due to late onset toxicities.
**Average sample size obtained from 2,000 simulated trials.
TITE-CRM: Time-o-event Continual Reassessment Method.
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